These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27376664)

  • 21. Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials.
    Bliziotis IA; Samonis G; Vardakas KZ; Chrysanthopoulou S; Falagas ME
    Clin Infect Dis; 2005 Jul; 41(2):149-58. PubMed ID: 15983909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current guidelines for the treatment of severe pneumonia and sepsis.
    Bodmann KF
    Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of Fluoroquinolone Resistance in Gram-Negative Bacteria Causing Bloodstream Infections.
    Dan S; Shah A; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2265-72. PubMed ID: 26833166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cephalosporin therapeutics for intensive care infections.
    Salacata A; Chow JW
    New Horiz; 1993 May; 1(2):181-6. PubMed ID: 7922401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Attributable mortality of ICU-acquired bloodstream infections: Impact of the source, causative micro-organism, resistance profile and antimicrobial therapy.
    Adrie C; Garrouste-Orgeas M; Ibn Essaied W; Schwebel C; Darmon M; Mourvillier B; Ruckly S; Dumenil AS; Kallel H; Argaud L; Marcotte G; Barbier F; Laurent V; Goldgran-Toledano D; Clec'h C; Azoulay E; Souweine B; Timsit JF;
    J Infect; 2017 Feb; 74(2):131-141. PubMed ID: 27838521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the efficacy and safety of isepamicin compared with amikacin in the treatment of nosocomial pneumonia and septicaemia.
    Beaucaire G
    J Chemother; 1995 Jun; 7 Suppl 2():165-73. PubMed ID: 8622107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is double coverage of gram-negative organisms necessary?
    Johnson SJ; Ernst EJ; Moores KG
    Am J Health Syst Pharm; 2011 Jan; 68(2):119-24. PubMed ID: 21200057
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia.
    Scaglione F; Esposito S; Leone S; Lucini V; Pannacci M; Ma L; Drusano GL
    Eur Respir J; 2009 Aug; 34(2):394-400. PubMed ID: 19213786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials.
    Falagas ME; Matthaiou DK; Bliziotis IA
    J Antimicrob Chemother; 2006 Apr; 57(4):639-47. PubMed ID: 16501057
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled Trials.
    Jiao Y; Moya B; Chen MJ; Zavascki AP; Tsai H; Tao X; Sutaria DS; Louie A; Boyce JD; Deveson Lucas D; Kim TH; Tsuji BT; Bonomo RA; Drusano GL; Bulitta JB
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 30988147
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is fluoroquinolone monotherapy a useful alternative treatment for Pseudomonas aeruginosa bacteraemia?
    Wu PF; Lin YT; Wang FD; Yang TC; Fung CP
    Infection; 2018 Jun; 46(3):365-373. PubMed ID: 29556979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in multidrug-resistant gram-negative bacilli and the role of prolonged β-lactam infusion in the intensive care unit.
    Guervil DJ; Chau T
    Crit Care Nurs Q; 2013; 36(4):345-55. PubMed ID: 24002425
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibiotic therapy for gram-negative bacteremia.
    Calandra T; Cometta A
    Infect Dis Clin North Am; 1991 Dec; 5(4):817-34. PubMed ID: 1783770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of aerosolized aminoglycosides in the treatment of Gram-negative ventilator-associated pneumonia.
    Mohr AM; Sifri ZC; Horng HS; Sadek R; Savetamal A; Hauser CJ; Livingston DH
    Surg Infect (Larchmt); 2007 Jun; 8(3):349-57. PubMed ID: 17635058
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials.
    Marcus R; Paul M; Elphick H; Leibovici L
    Int J Antimicrob Agents; 2011 Jun; 37(6):491-503. PubMed ID: 21292449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monotherapy versus beta-lactam-aminoglycoside combination therapy for gram-negative bacteremia.
    Falagas ME
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2593-4. PubMed ID: 9371379
    [No Abstract]   [Full Text] [Related]  

  • 38. Fluoroquinolone use and fluoroquinolone resistance: is there an association?
    Richard P; Delangle MH; Merrien D; Barillé S; Reynaud A; Minozzi C; Richet H
    Clin Infect Dis; 1994 Jul; 19(1):54-9. PubMed ID: 7948558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base.
    Abdul-Aziz MH; Portunato F; Roberts JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):501-510. PubMed ID: 33009140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study).
    Albasanz-Puig A; Gudiol C; Puerta-Alcalde P; Ayaz CM; Machado M; Herrera F; Martín-Dávila P; Laporte-Amargós J; Cardozo C; Akova M; Álvarez-Uría A; Torres D; Fortún J; García-Vidal C; Muñoz P; Bergas A; Pomares H; Mercadal S; Durà-Miralles X; García-Lerma E; Pallarès N; Carratalà J
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0004521. PubMed ID: 33972253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.